Merck’s investigational prostaglandin analogue ophthalmic medication tafluprost meets primary endpoint in phase III study
Monday, May 2, 2011 - 09:31
in Mathematics & Economics
WHITEHOUSE STATION, N.J., May 2, 2011 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new Phase III data showed that patients with open-angle glaucoma...